Atherosclerotic cardiovascular disease
diseaseOn this page
Summary
Atherosclerotic cardiovascular disease (MONDO:1060134) is a disease and 120 clinical trials. Top therapeutic interventions include evolocumab, alirocumab, and bempedoic acid. A subtype of atherosclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 120
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | atherosclerotic cardiovascular disease |
| Mondo ID | MONDO:1060134 |
| NCIT | C35771 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of atherosclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › arteriosclerosis disorder › atherosclerosis › atherosclerotic cardiovascular disease
Related subtypes (5): aortic atherosclerosis, generalized atherosclerosis, cerebral atherosclerosis, coronary atherosclerosis, autoimmune atherosclerosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 120.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 63 |
| PHASE3 | 25 |
| PHASE4 | 12 |
| PHASE2 | 10 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05749874 | PHASE4 | ACTIVE_NOT_RECRUITING | Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus |
| NCT06249165 | PHASE4 | ACTIVE_NOT_RECRUITING | VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease |
| NCT07034690 | PHASE4 | RECRUITING | Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia |
| NCT07581808 | PHASE4 | NOT_YET_RECRUITING | Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention |
| NCT00856817 | PHASE4 | TERMINATED | Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation |
| NCT03096288 | PHASE4 | COMPLETED | Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity |
| NCT03228017 | PHASE4 | COMPLETED | Subclinical Cardiovascular Disease in Psoriatic Disease |
| NCT03403556 | PHASE4 | UNKNOWN | High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes |
| NCT03597412 | PHASE4 | COMPLETED | Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM |
| NCT03626831 | PHASE4 | COMPLETED | Effect of Evolocumab on Vascular Function |
| NCT05761444 | PHASE4 | COMPLETED | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients |
| NCT05976893 | PHASE4 | UNKNOWN | Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer |
| NCT01252953 | PHASE3 | ACTIVE_NOT_RECRUITING | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification |
| NCT03705234 | PHASE3 | ACTIVE_NOT_RECRUITING | A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease |
| NCT05030428 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
| NCT05202509 | PHASE3 | ACTIVE_NOT_RECRUITING | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease |
| NCT05485961 | PHASE2/PHASE3 | RECRUITING | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
| NCT05581303 | PHASE3 | ACTIVE_NOT_RECRUITING | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial |
| NCT06292013 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
| NCT06383390 | PHASE3 | ACTIVE_NOT_RECRUITING | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
| NCT06494501 | PHASE3 | RECRUITING | The Prevent Coronary Artery Disease Trial |
| NCT06813911 | PHASE3 | RECRUITING | Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD |
| NCT06875973 | PHASE3 | RECRUITING | Pelacarsen Roll-over Extension Program |
| NCT06930885 | PHASE3 | RECRUITING | Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease |
| NCT07037433 | PHASE3 | RECRUITING | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity |
| NCT07157774 | PHASE3 | RECRUITING | Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) |
| NCT07551492 | PHASE3 | NOT_YET_RECRUITING | A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease |
| NCT00185185 | PHASE3 | COMPLETED | Olmesartan Medoxomil in Atherosclerosis |
| NCT01353066 | PHASE2/PHASE3 | UNKNOWN | Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM) |
| NCT01572259 | PHASE3 | UNKNOWN | Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism |
| NCT01663402 | PHASE3 | COMPLETED | ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab |
| NCT02576067 | PHASE3 | COMPLETED | Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study |
| NCT02666664 | PHASE3 | COMPLETED | Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony) |
| NCT02988115 | PHASE3 | COMPLETED | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant |
| NCT02991118 | PHASE3 | COMPLETED | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk |
| NCT03067441 | PHASE3 | COMPLETED | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) |
| NCT04807400 | PHASE3 | COMPLETED | Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support |
| NCT04929249 | PHASE3 | COMPLETED | A Randomized Study to Evaluate the Effect of an Inclisiran First Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) |
| NCT05142722 | PHASE3 | COMPLETED | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies |
| NCT07311330 | PHASE2 | NOT_YET_RECRUITING | Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| EVOLOCUMAB | 4 | 5 |
| ALIROCUMAB | 4 | 4 |
| BEMPEDOIC ACID | 4 | 4 |
| PITAVASTATIN | 4 | 2 |
| ATENOLOL | 4 | 1 |
| CIPROFIBRATE | 4 | 1 |
| FISH OIL | 4 | 1 |
| HYDROCHLOROTHIAZIDE | 4 | 1 |
| INCLISIRAN SODIUM | 4 | 1 |
| OLIVE OIL | 4 | 1 |
| OLMESARTAN MEDOXOMIL | 4 | 1 |
| INCLISIRAN | 3 | 14 |
| ANACETRAPIB | 3 | 2 |
| OBICETRAPIB | 3 | 2 |
| PELACARSEN | 3 | 2 |
| ARGININE | 3 | 1 |
| BEZAFIBRATE | 3 | 1 |
| HEME ARGINATE | 3 | 1 |
| LEPODISIRAN SODIUM | 3 | 1 |
| OLEZARSEN | 3 | 1 |
| OLPASIRAN | 3 | 1 |
| RETATRUTIDE | 3 | 1 |
| BMS-823778 | 2 | 1 |
| ESATENOLOL | 2 | 1 |
| MARIDEBART CAFRAGLUTIDE | 2 | 1 |
| MUVALAPLIN | 2 | 1 |
| PLOZALIZUMAB | 2 | 1 |
| CHEMBL3787505 | 0 | 2 |
| CHEMBL1230004 | 0 | 1 |
| CHEMBL3739769 | 0 | 1 |